Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet

Kidney International

Volumn 65, Issue 3, 2004, Pages 951-960

  Onozato, Maristela Lika ^a   Tojo, Akihiro ^a   Goto, Atsuo ^a   Fujita, Toshiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Adhesion molecule; Diabetic nephropathy; Gliclazide; NAD(P)H oxidase; Nitric oxide synthase; Reactive oxygen species

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; HYDROGEN PEROXIDE; INTERCELLULAR ADHESION MOLECULE 1; MANGANESE SUPEROXIDE DISMUTASE; NITRIC OXIDE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SCAVENGER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL DIET; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; FEMALE; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; LIPID PEROXIDATION; MACROPHAGE MIGRATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TISSUE LEVEL;

EID: 1342322651     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00470.x     Document Type: Article

References (39)

1. CAI H, HARRISON DG: Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 87:840-844, 2000
2. HA H, LEE HB: Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int 58(Suppl 77):S19-S25, 2000
3. BOOTH G, STALKER TJ, LEFER AM, SCALIA R: Mechanisms of amelioration of glucose-induced endothelial dysfunction following inhibition of protein kinase C in vivo. Diabetes 51:1556-1564, 2002
4. CHABRASHVILI T, TOJO A, ONOZATO ML, et al: Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 39:269-274, 2002
5. ONOZATO ML, TOJO A, GOTO A, et al: Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: Effects of ACEI and ARB. Kidney Int 61:186-194, 2002
6. GRIENDLING KK, MINIERI CA, OLLERENSHAW JD, ALEXANDER RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74:1141-1148, 1994
7. PAGANO PJ, CLARK JK, CIFUENTES-PAGANO ME, et al: Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: Enhancement by angiotensin II. Proc Natl Acad Sci USA 94:14483-14488, 1997
8. MOLLNAU H, WENDT M, SZOCS K, et al: Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90:E58-E65, 2002
9. TOJO A, ONOZATO ML, KOBAYASHI N, et al: Angiotensin II and oxidative stress in Dahl salt-sensitive rat with heart failure. Hypertension 40:834-839, 2002
10. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
11. PARVING HH, LEHNERT H, BROCHNER-MORTENSEN J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
12. LEWIS EJ, HUNSICKER LG, CLARKE WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
13. BRENNER BM, COOPER ME, DE ZEEUW D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
14. NASSAR T, KADERY B, LOTAN C, et al: Effects of the superoxide dismutase-mimetic compound tempol on endothelial dysfunction in streptozotocin-induced diabetic rats. Eur J Pharmacol 436:111-118, 2002
15. SCHNACKENBERG CG, WILCOX CS: The SOD mimetic tempol restores vasodilation in afferent arterioles of experimental diabetes. Kidney Int 59:1859-1864, 2001
16. CHUGH SN, DHAWAN R, KISHORE K, et al: Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus - A double blind randomized study. J Assoc Physicians India 49:803-807, 2001
17. JENNINGS PE: Vascular benefits of gliclazide beyond glycemic control. Metabolism 49:17-20, 2000
18. O'BRIEN RC, LUO M, BALAZS N, MERCURI J: In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications 14:201-206, 2000
19. ZOU MH, SHI C, COHEN RA: High glucose via peroxynitrite causes tyrosine nitration andinactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes 51:198-203, 2002
20. BROWNLEE M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001
21. FURUTA T, SAITO T, OOTAKA T, et al: The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 21:480-485, 1993
22. SCHEUER H, GWINNER W, HOHBACH J, et al: Oxidant stress in hyperlipidemia-induced renal damage. Am J Physiol Renal Physiol 278:F63-F74, 2000
23. BRUNEVAL P, BARIETY J, BELAIR MF, et al: Mesangial expansion associated with glomerular endothelial cell activation and macrophage recruitment is developing in hyperlipidaemic apoE null mice. Nephrol Dial Transplant 17:2099-2107, 2002
24. BREMER V, TOJO A, KIMURA K, et al: Role of nitric oxide in rat nephrotoxic nephritis: Comparison between inducible and constitutive nitric oxide synthase. J Am Soc Nephrol 8:1712-1721, 1997
25. NISHIKAWA T, EDELSTEIN D, BROWNLEE M: The missing link: A single unifying mechanism for diabetic complications. Kidney Int 58 (Suppl 77):S26-S30, 2000
26. RENIER G, DESFAITS AC, SERRI O: Gliclazide decreases low-density lipoprotein oxidation and monocyte adhesion to the endothelium. Metabolism 49:17-22, 2000
27. HINK U, LI H, MOLLNAU H, et al: Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88:E14-E22, 2001
28. STULAK JM, LERMAN A, CACCITOLO JA, et al: Impaired renal vascular endothelial function in vitro in experimental hypercholesterolemia. Atherosclerosis 154:195-201, 2001
29. RODRIGUEZ JA, GRAU A, EGUINOA E, et al: Dietary supplementation with vitamins C and E prevents down regulation of endothelial NOS expression in hypercholesterolemia in vivo and in vitro. Atherosclerosis 165:33-40, 2002
30. KNOWLES JW, REDDICK RL, JENNETTE JC, et al: Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)ApoE(-/-) mice are ameliorated by enalapril treatment. J Clin Invest 105:451-458, 2000
31. LI H, WALLERATH T, MUNZEL T, FORSTERMANN U: Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide 7:149-164, 2002
32. HIRATA K, SHIKATA K, MATSUDA M, et al: Increased expression of selectins in kidneys of patients with diabetic nephropathy. Diabetologia 41:185-192, 1998
33. RODRIGUEZ-ITURBE B, PONS H, HERRERA-ACOSTA J, JOHNSON RJ: Role of immunocompetent cells in nonimmune renal diseases. Kidney Int 59:1626-1640, 2001
34. SUGIMOTO H, SHIKATA K, HIRATA K, et al: Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: Glomerular hyperfiltration is a potential mechanism of ICAM-1 up-regulation. Diabetes 46:2075-2081, 1997
35. BUSSOLATI B, MARIANO F, MIGLIORI M, CAMUSSI G: Nitric oxide/platelet activating factor cross-talk in mesangial cells modulates the interaction with leukocytes. Kidney Int 62:1322-1331, 2002
36. KLAHR S: Urinary tract obstruction. Semin Nephrol 21:133-145, 2001
37. ELHADD TA, NEWTON RW, JENNINGS PE, BELCH JJ: Antioxidant effects of gliclazide and soluble adhesion molecules in type 2 diabetes. Diabetes Care 22:528-530, 1999
38. KINOSHITA N, KAKEHASHI A, INODA S, et al: Effective and selective prevention of retinal leukostasis in streptozotocin-induced diabetic rats using gliclazide. Diabetologia 45:735-739, 2002
39. JERUMS G, MURRAY RM, SEEMAN E, et al: Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: A two-year controlled study. Diabetes Res Clin Pract 3:71-80, 1987